Drug Pipeline

RO7198457 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
3
Active Studies
2
Recruiting
3
Top Sponsors
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-09 NCT06534983
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus…		 Primary endpoint(s) modified
2026-06-09 NCT06534983
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus…		 Enrollment reduced: 362 -> 62 participants
Active Studies by Phase
Phase 2
2
Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT06534983 A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus… Muscle-invasive Urothelial Carcinoma Recruiting
NCT05968326 A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and… Adenocarcinoma, Pancreatic Ductal Recruiting
Phase 1
NCT04161755 Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With… Pancreatic Cancer Active, Not Recruiting
Sponsors Running RO7198457 Trials
Memorial Sloan Kettering Cancer Center (1) Genentech, Inc. (1) Hoffmann-La Roche (1)
Disease Areas
Pancreatic Cancer (1) Bladder Cancer (1)
Get alerts when RO7198457 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free